New drug combo aims to tackle Hard-to-Treat multiple myeloma

NCT ID NCT04661137

Terminated Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests the drug selinexor combined with one of three other cancer drugs (carfilzomib, daratumumab, or pomalidomide) in 96 adults with multiple myeloma whose disease has worsened despite current treatment. Participants continue on the combination until the cancer progresses, side effects become unmanageable, or they choose to stop. The main goal is to see how many patients respond to the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor (KPT-330) combined with carfilzomib, daratumumab, or pomalidomide
What this could lead to: If successful, this could offer a new treatment option for multiple myeloma patients whose cancer has stopped responding to their current therapy.
What could go wrong: This is an early-phase (2B) trial that was suspended, so results are uncertain. The combination drugs can cause significant side effects, and the study may not show enough benefit to continue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

John Theurer Cancer Center

Hackensack, New Jersey, 07601, United States
Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.